Last week, Hims & Hers Health (HIMS, Financial) dropped another mic with its latest earnings, and the numbers are mind-blowing. Revenue? Up 77% year-over-year to $401.6 million—blowing past every forecast in sight. Subscribers? Over 2 million, up 44% in just a year. Adjusted EBITDA? A jaw-dropping $51.1 million, more than quadruple last year's. And if that wasn't enough to turn heads, the company bumped its full-year revenue outlook to $1.465 billion. This isn't just growth—it's rocket fuel for a business that's redefining personalized healthcare.
Wall Street's big players are paying attention. Today, Robeco Institutional Asset Management, Diversify Advisory Services, and other institutional investors have all boosted their stakes, with a hefty 63.52% of the stock now in institutional hands. Meanwhile, insider moves are making waves too. Over the past several months, CEO Andrew Dudum and CFO Oluyemi Okupe sold some shares but held onto significant positions—always a confidence signal. Analysts are buzzing as well, with TD Cowen raising its price target to $28, citing HIMS' diverse revenue streams and minimal reliance on buzzy GLP-1 weight-loss drugs (which account for less than 10% of revenue).
And that's the kicker: Hims & Hers isn't banking everything on trendy weight-loss solutions. The company's secret sauce is its compounding personalization strategy, offering tailored solutions for everything from mental health to skincare. With a forward P/E under 28 and a ridiculously low PEG ratio of 0.15, HIMS is a bargain for the growth it's delivering. Throw in next year's plans to launch generic GLP-1 options, and you've got a long-term winner. Sure, the stock might see some bumps—it's been volatile—but this is a rare, transformational player in the telehealth space that investors should keep front and center.
